Literature DB >> 9169719

Breast-conserving radiation therapy: potential of inverse planning with intensity modulation.

M C Smitt1, S D Li, C A Shostak, W Chang, A L Boyer.   

Abstract

PURPOSE: To evaluate inverse planning with beam-intensity modulation in breast-conserving radiation therapy.
MATERIALS AND METHODS: A prototype inverse treatment-planning system was used in five patients with early-stage breast tumors. The prescription for the breast was 5,040 cGy in 180-cGy fractions, with the primary tumor site receiving 6,000 cGy in 214-cGy fractions. Isodose distributions from the prototype were compared section by section with those from conventional three-dimensional planning.
RESULTS: The inverse planning system showed dose variation of 84%-98% to 111%-113% in the primary tumor site. For whole-breast irradiation, 95% of the target volume received at least 4,000 cGy. High-dose areas were adjacent to the primary site. Lower-dose areas were in the most medial part of the breast. Compared with the conventional system, target doses were similar. The volume of lung and heart that received high doses was smaller; however, larger lung and heart volumes received doses of less than 1,200 cGy.
CONCLUSION: Intensity modulation may accomplish "concomitant boost" treatment. Acceptable dose gradients are achieved in the target volumes, with lower volumes of high-dose treatment in normal tissue. Plans that required comprehensive nodal radiation, in particular, were improved relative to conventional plans. Optimization of the planning system is needed to minimize the lung and heart volumes that receive low-dose radiation.

Entities:  

Mesh:

Year:  1997        PMID: 9169719     DOI: 10.1148/radiology.203.3.9169719

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

1.  Dosimetric feasibility of an "off-breast isocenter" technique for whole-breast cancer radiotherapy.

Authors:  Juan-Francisco Calvo-Ortega; Sandra Moragues; Miquel Pozo; Joan Casals
Journal:  Rep Pract Oncol Radiother       Date:  2016-08-24

2.  Acute Toxicity From Breast Cancer Radiation Using Helical Tomotherapy With a Simultaneous Integrated Boost.

Authors:  Andrzej P Wojcieszynski; Anna K Olson; Yi Rong; Randall J Kimple; Poonam Yadav
Journal:  Technol Cancer Res Treat       Date:  2015-03-16

3.  Initial validation and clinical experience with 3D optical-surface-guided whole breast irradiation of breast cancer.

Authors:  S Li; T DeWeese; B Movsas; Dezhi Liu; Deborah Frassica; Jinkoo Kim; Qing Chen; Eleanor Walker
Journal:  Technol Cancer Res Treat       Date:  2012-02

4.  Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer.

Authors:  Reshma Jagsi; Jean Moran; Robin Marsh; Kathryn Masi; Kent A Griffith; Lori J Pierce
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-09-09       Impact factor: 7.038

Review 5.  Radiation therapy planning with photons and protons for early and advanced breast cancer: an overview.

Authors:  Damien C Weber; Carmen Ares; Antony J Lomax; John M Kurtz
Journal:  Radiat Oncol       Date:  2006-07-20       Impact factor: 3.481

6.  HDR brachytherapy combined with 3-D conformal vs. IMRT in left-sided breast cancer patients including internal mammary chain: comparative analysis of dosimetric and technical parameters.

Authors:  Rajesh Ashok Kinhikar; Sudesh Sharad Deshpande; Umesh Mahantshetty; Rajiv Sarin; Shyam Kishore Shrivastava; Deepak Dattatraya Deshpande
Journal:  J Appl Clin Med Phys       Date:  2005-08-12       Impact factor: 2.102

7.  Intensity-modulated radiation therapy with simultaneous integrated boost for locally advanced breast cancer: a prospective study on toxicity and quality of life.

Authors:  David Pasquier; Florence Le Tinier; Raoudha Bennadji; Anais Jouin; Samy Horn; Alexandre Escande; Emmanuelle Tresch; Marie Pierre Chauvet; Audrey Mailliez; Frederik Crop; Xavier Mirabel; Eric Lartigau
Journal:  Sci Rep       Date:  2019-02-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.